



THE REACTION TIMES

All the news that's fit to react to.

Published twice a year by the ACS Division of Medicinal Chemistry



Volume 12, Number 2

Summer Newsletter

August 9, 2013

NEW Abstracts for the Indianapolis ACS Meeting
Are Available for Download

Abstracts for the upcoming Indianapolis ACS meeting are available on the Division web site. Follow the link below to download the MEDI abstracts for the Indianapolis ACS meeting:

<http://www.acsmedchem.org/mediabstractf2013.pdf>

**ACS Division of Medicinal Chemistry
Quick Reference Guide to Services**

Division Web Site: <http://www.acsmedchem.org>

Division Hall of Fame:
<http://www.acsmedchem.org/hofmain.html>

Link to Division Newsletter Archive:
<http://www.acsmedchem.org/nl.html>

Link to Archived MEDI Meeting Abstracts:
<http://www.acsmedchem.org/abstracts.html>

ACS Web Page
<http://portal.acs.org/portal/acs/corg/content>

Journal of Medicinal Chemistry
<http://pubs.acs.org/journal/jmcmr>

2013 Executive Committee Members

2013 Chair: Joel Barrish
2013-2014 Program Chair: John E. Macor
2013 Vice-Chair: Thomas Prisinzano
Industrial Councilor 2013-15: Amy Ripka
Industrial Councilor 2012-14: William J. Greenlee
Academic Councilor 2011-13: Richard A. Gibbs
Academic Councilor 2012-14: David P. Rotella
Secretary/PR Chair 2011-13: D. Eric Walters
Membership Chair: Yanping Xu
Treasurer 2012-14: Danny Lattin
2013 Past Chair: Patrick M. Woster

Contact information for all Division Officers appears at the end of this Newsletter.

**Scientific Program for the Indianapolis ACS Meeting
(Sept 8-13, 2013)**


(ACS Abstract system now closed for this meeting)

SUN AM	Modulating the Epigenome I
SUN AM	Targeting Aberrant Circadian Rhythm
SUN AM	General Oral Session I
SUN PM	Modulating the Epigenome II
SUN PM	Immune System / Small Molecules
SUN PM	General Oral Session II
SUN EVE	Poster Session I and Social Hour
MON AM	Drug Metabolism & Disposition
MON AM	"Middle Space" Macrocycles
MON PM	Targeting Cancer Stem Cells
MON PM	Prosecuting High Throughput Screening Hits
TUES AM	Advanced Material Designs
TUES AM	Antibody-Drug Conjugates
TUES PM	Cancer and Metabolic Pathways
TUES PM	Awards Symposium
WED AM	Toolbox: Conformation
WED AM	Alzheimer's Disease
WED AM	General Oral Session III
WED PM	First Time Disclosures
WED PM	General Oral Session IV
WED EVE	Poster Session II

**Scientific Program for the Dallas ACS Meeting (March
15-20, 2014)**

(ACS Abstract system opens late August!)

SUN AM	Small Molecules in Chemical Biology
SUN AM	Neuropathic Pain
SUN AM	General Oral Session I
SUN PM	Young Investigators' Symposium
SUN PM	General Oral Session II
SUN EVE	Poster Session I and Social Hour
MON AM	Tuberculosis: Biology and Emerging Therapeutics
MON AM	G-Quadruplexes as Drug Targets
MON PM	New Approaches to Third World Diseases
MON PM	Chemical Oncology: Beyond kinases
TUES AM	New Directions for TRP Channel Modulators
TUES AM	Metabolomics in Drug Discovery
TUE NOON	Lunch and Learn
TUES PM	Exploiting the 3rd Dimension in Drug Design
TUES PM	Therapies for Orphan Diseases
WED AM	Bioavailability from Non-traditional Routes
WED AM	Targeting Cancer Past the Blood Brain Barrier
WED AM	General Oral Session III
WED PM	First Time Disclosures
WED PM	General Oral Session IV
WED EVE	Poster Session II



BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Digests

Cutting Edge Research

Editor

Peter Bernstein, Consultant – PharmaB LLC; Senior Principal Scientist AstraZeneca (retired), and Member of the ACS Division of Medicinal Chemistry Hall of Fame, has been appointed to ensure a regular flow of reviews on trending topics by the best author.

Features of DIGESTS Papers:

- Short, authoritative overviews of current status and future directions
- Cover areas of high topicality
- 4-6 pages in length
- Peer reviewed
- Widely read
- Highly cited


FREE BMCL DIGESTS

Would you like to read all BMCL Digests articles published to date?

Visit: www.elsevier.com/locate/bmcl

Topics currently covered:

- Carbonic anhydrase inhibitors
- Understanding drugs and diseases by systems biology
- Fluorescent Ligands for Adenosine Receptors
- Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease
- Small molecule inhibitors of BRAF in clinical trials
- The quest for oral factor Xa inhibitors
- Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules
- The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH)
- Recent Developments in Targeting Protein Misfolding Diseases
- Learning from our mistakes: the unknown knowns in fragment screening
- The Mammalian Clock and Chronopharmacology
- Future directions in phosphodiesterase drug discovery
- Using Hydrogen Bond Strength and Intramolecular Hydrogen Bonds to Modulate P-glycoprotein Transport and Passive Permeability
- Melanin concentrating hormone receptor 1 (MCHR1) antagonists - Still a viable approach for obesity treatment?



WHAT TOPIC WOULD YOU LIKE TO SEE AS A BMCL DIGEST ARTICLE?

If you have a suggestion for a topic that you would like to see, please contact Peter Bernstein at: BMCL_Digests@elsevier.com.

*Part of the Tetrahedron
family of journals*

Top 25 Hottest articles ScienceDirect

CHEMISTRY > BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Digests are proving to be among the hottest articles in BMCL!

Visit: <http://top25.sciencedirect.com>

Ghosh, Roth, and Wani elected to Medicinal Chemistry Hall of Fame

The Division is pleased to announce that three medicinal chemists, Arun K. Ghosh, Bruce D. Roth, and Mansukh C. Wani, will be inducted into the ACS Division of Medicinal Chemistry Hall of Fame at the Indianapolis ACS meeting. The induction ceremony will be held on Tuesday, August 21, 2012, from 4:30 - 7:30 p.m., in the Indiana Convention Center, Ballroom 500.



Dr. Arun K. Ghosh was born in Calcutta, India and obtained his B.S. degree in (1979) and his M.S. degree in Chemistry (1981) from Calcutta University and the Indian Institute of Technology, Kanpur, India respectively. He received his Ph.D. in organic chemistry (1985) from University of Pittsburgh and was a postdoctoral fellow with E. J. Corey at Harvard University (1985-1988). Arun joined Merck Research Laboratories as a medicinal chemist in 1988. In 1994, he began his independent academic career as an Assistant Professor in the Department of Chemistry, University of Illinois, Chicago. After promotion to Professor in 1998, Arun moved to Purdue University in 2005 where he is currently the Ian P. Rothwell Distinguished Professor of Chemistry and Medicinal Chemistry & Molecular Pharmacology.

Professor Ghosh's research interests have bridged the areas of bioorganic, medicinal and synthetic chemistry. He has made notable contributions in the structure-based design and development of human medicine. Noteworthy is his discovery of Darunavir, the first FDA approved treatment for drug resistant HIV in 2006. His research efforts on Alzheimer's Disease set the stage for structure-based drug design efforts on β -secretase inhibitors, determination of the first X-ray crystal structure of inhibitor-bound β -secretase-1, development of tools for selectivity design, and identification of inhibitors for clinical development. Ghosh has developed numerous conceptual tools for protein-structure-based drug-design, drug optimization and development. These include, backbone binding concept for designing of HIV-1 protease inhibitors to combat drug resistance, introduction of urethanes of stereochemically defined cyclic ethers and cyclic sulfones in drug design, protein-structure-based design of selectivity for β -secretase inhibitors for Alzheimer's Disease and design of reversible and irreversible inhibitors against corona virus proteases. He has completed chemical syntheses of numerous targets, covering over three dozen different structural families, including bioactive targets such as Laulimalide, Peloruside, Dolicolide, Zapanolide, Lasanolide, Platensin and Platensomycin. Ghosh's synthetic and mechanistic studies led to the discovery that the natural products laulimalide and pelorusides are potent against taxol resistant cell lines, bind to a novel drug-binding site on tubulin and show a synergistic effect with taxol. Ghosh has developed many new synthetic methodologies involving asymmetric syn- and anti-selective adol reactions, asymmetric catalytic Diels-Alder, hetero Diel-Alder, Prins cyclization and asymmetric multicomponent reactions where multiple chiral centers are set in a single one-pot operation.


Professor Ghosh has been awarded the Chemical Research Society of India Medal (2012); MERIT Award, National Institutes of Health (2011); IUPAC-Richter Prize in Medicinal Chemistry (2010); American Chemical Society's Arthur C. Cope Senior Scholar Award (2010); Jeananne D. and James B. Chaney Research and Scholarship Achievement Award (2010); and ACS Robert Scarborough Excellence in Medicinal Chemistry Award (2008). He was elected as a member of American Association for the Advancement of Science (2005). Arun is the author of over 245 scientific research publications and over 50 US patents and patent applications.

Bruce Roth received his BS in Chemistry from St. Joseph's College in Philadelphia, PA (1976). He then moved to Iowa State University where he received his Ph.D. in Synthetic Organic Chemistry (1981) under the direction of Dr. George A. Kraus. Bruce then underwent postdoctoral training under the direction of Dr. Andrew S. Kende at the University of Rochester where he completed the total synthesis of the insect antifeedant (\pm)-Ajugarin IV and the anticancer agent (\pm)-Quadrone. In 1982, Bruce joined the Atherosclerosis Chemistry Section of the Warner-Lambert/Parke-Davis Co located in Ann Arbor, MI. As part of a project aimed at discovering inhibitors of cholesterol biosynthesis, Bruce synthesized the compound that would ultimately be marketed as Lipitor®. For his invention of



Lipitor®, Bruce received the 1997 Warner-Lambert Chairman's Distinguished Scientific Achievement Award, the 1999 "Inventor of the Year Award" from the New York Intellectual Property Law Association, the 2003 American Chemical Society Award for Creative Invention, the 2003 Gustavus J. Esselen Award for Chemistry in the Public Interest, sponsored by the North East Region Section of the American Chemical Society, the 2005 Distinguished Achievement Award from Iowa State University and a 2006 Pfizer Global Research and Development Achievement Award. After taking on progressively greater leadership responsibilities at Parke-Davis and Pfizer, Bruce served as Vice President of Chemistry at the Pfizer Global Research and Development, Ann Arbor Laboratories from 2000- 2007. He also served as an adjunct associate professor in the Department of Medicinal Chemistry in the School of Pharmacy of the University of Michigan from 1996-2007.

In May 2007, Bruce joined Genentech Small Discovery as Senior Director of Discovery Chemistry. On August 10, 2008 he was named one of the American Chemical Society Heroes in Chemistry for the Discovery and Development of Lipitor. In 2010, Bruce was promoted to Vice President of Discovery Chemistry. Dr. Roth is the inventor or co-inventor of 43 issued U.S. patents and the author or coauthor of 50 manuscripts, 35 published abstracts, 9 book chapters and review articles and has given more than 20 invited lectures.



Mansukh C. Wani was born in Nandurbar, Maharashtra, India. He attended grade school in Nandurbar, Maharashtra and graduated in 1943. He then received his bachelor's degree in Chemistry from the University of Bombay in 1947 and his master's degree in Organic Chemistry from the same University in 1950. In 1958, he came to the United States of America and obtained his Ph.D. degree in Chemistry from Indiana University at Bloomington in 1962, followed by a postdoctoral fellowship at the University of Wisconsin at Madison. He joined the Research Triangle Institute (RTI) in North Carolina in 1962, where he currently holds the position of Principal Scientist (Emeritus).

Dr. Wani's main areas of research have included the isolation and characterization of biologically active natural products and synthesis of anticancer and antifertility agents. In the area of natural products research at RTI, he has been involved in the isolation, purification, and characterization of a wide variety of antineoplastic agents including camptothecin and taxol. These extremely important


leads have contributed to the development of four prescription drugs (irinotecan and topotecan from camptothecin, and paclitaxel and docetaxel from Taxol), which together accounted for about one-third of the total cancer chemotherapeutic agent market in 2002. In addition to this ongoing work on plant-derived antitumor agents, continuing efforts have also been directed towards the synthesis of potent water-soluble camptothecin analogs. He has published extensively with over 200 publications and 36 patents to his credit. He has been an invited speaker to a number of national and international symposia on taxol and camptothecin.

Dr. Wani is the recipient of many awards, including the Bruce F. Cain Memorial Award given by the American Association for Cancer Research, the City of Medicine Award given by the Greater Durham Chamber of Commerce, and the National Cancer Institute Award of Recognition, the 2000 Charles F. Kettering Prize of the General Motors Cancer Research Foundation, the Ranbaxy Research Award from the Ranbaxy Science Foundation, and the 2003 Distinguished Alumni Award from Indiana University. In August 2002, a plaque commemorating the discovery of Taxol at RTI was unveiled by the Gifford Pinchot National Forest of Washington State, and in April 2003, the American Chemical Society designated the discovery of camptothecin and Taxol at RTI a National Historic Chemical Landmark. In 2005, Dr. Wani received the North Carolina Award in Science from the Governor of North Carolina. In 2008, Dr. Wani received the Paul Ehrlich Magic Bullet Lifetime Achievement Award.


Interdisciplinary, professional, medical titles from the Royal Society of Chemistry

TAKE ADVANTAGE OF OUR EXCLUSIVE 20% DISCOUNT OFFER – OPEN TO THE ACS DIVISION OF MEDICINAL CHEMISTRY

Toxicology




Aging and Vulnerability to Environmental Chemicals
ISBN 978-1-84973-418-9
\$246.00




Chemical Toxicity Prediction
ISBN 978-1-84973-384-7
\$190.00

Targeting disease




Comprehensive Biomarker Discovery and Validation for Clinical Application
ISBN 978-1-84973-422-6
\$260.00



New Therapeutic Strategies for Type 2 Diabetes
ISBN 978-1-84973-414-1
\$260.00

Drug discovery



Inhibitors of Molecular Chaperones as Therapeutic Agents
ISBN 978-1-84973-666-4
\$260.00



Drug Discovery for Psychiatric Disorders
ISBN 978-1-84973-365-6
\$255.00



Successful Strategies for the Discovery of Antiviral Drugs
ISBN 978-1-84973-657-2
\$260.00



Drug Discovery from Natural Products
ISBN 978-1-84973-361-8
\$260.00

Visit the RSC website, navigate to the individual book page and select "PROMOTIONAL OFFER – 20%" from the drop down menu. Enter the discount code "REACTION TIMES _ 2013" at the shopping cart stage.

We would like to extend this EXCLUSIVE 20% DISCOUNT OFFER to the ACS Division of Medicinal Chemistry members across any RSC title until the end of 2013.

Proposal to Change the Name of the Division of Medicinal Chemistry

The Division's Executive Committee met in New Orleans prior to the most recent ACS National Meeting to formulate a strategic plan for the Division for the next 5 years (the new Strategic Plan can be found on the Division's website). The committee considered the current strengths, weaknesses, opportunities and threats to the division, its mission and service to members. The core skills associated with chemistry remain a central asset and uniting theme for drug discovery scientists. However, this analysis suggested that the role of the medicinal chemist has evolved considerably in the last several years; traditional small molecule therapeutics are no longer their exclusive focus. Today's medicinal chemist works on any and all modalities – peptides, proteins, antibodies – that can address a biological question, whether it is the discovery of a new therapeutic or, for example, the identification and validation of a new biological target. Current MEDI programming at ACS national meetings reflects this expanded role and, in an effort to attract drug discovery scientists who are not trained as chemists, the division's executive committee recommends changing the name of the division to the "Division of Drug Discovery". Coupled with this is a proposal to revise the title for *Annual Reports in Medicinal Chemistry (ARMC)*, the Division's most important benefit, to *Annual Reports in Drug Discovery*. Since 1965, ARMC has been dedicated to furthering legitimate interest in learning, chronicling and sharing information on the discovery of compounds and the methods that lead to new therapeutic advances. ARMC, sent to MEDI members annually at no additional cost, covers disease-based reviews and highlights emerging technologies of interest to chemists engaged in drug discovery. These changes maintain the well established linkage between the Division and this important publication.


The most important reason to revise the name of the Division is the recognition that our discipline has evolved to include both a wide range of techniques for the study of biologically active compounds and the development of 'tool' molecules to aid the overall drug discovery process. Identification of a novel biological target or elucidation of a cellular pathway is as important for the drug discovery chemist as is the synthesis of a therapeutic agent for clinical studies. Medicinal chemists partner with scientists across many disciplines on all aspects of drug discovery and development. From target identification to high throughput screening and hit identification, to hit and lead optimization, to biomarkers and translational medicine, medicinal chemistry and associated chemical and biological sciences are completely interconnected in their pursuit to address drug discovery challenges. The benefits of including all of these scientists in the division range from more diverse programming at various Division--sponsored events, expanded training and educational opportunities for students, and the recognition that the Division sees itself as the world's authority on the subject of drug discovery broadly defined. This revised description of the Division can potentially address one of its most pressing threats: stagnant membership associated with contraction of industrial R & D organizations, limiting the ability of the division to provide the range of services attractive to members. Full details on these services are included in the new strategic plan posted at the division's web site.

The Executive Committee recognized that one of the keys to growth and development of the Division is engagement of young scientists. Revising the Division's name to better describe the activity of its members is a logical way to demonstrate the range of skills encompassed by drug discovery and interest the next generation of drug discovery scientists. Programming at Division--sponsored events at ACS local and national meetings and national drug discovery symposia reflect this evolution and bring consistency to the message that the division is an international source for expertise on the subject.

The process for changing the name of an ACS division is outlined in the Society's bylaws and includes a vote by division members at an open business meeting. This meeting will be held during the 246th ACS National Meeting at 7 PM on Sunday, September 8th, 2013 in Room 207 of the Indianapolis Convention Center. If a two thirds majority of the membership present at the meeting approves the change, a formal petition will be filed with the Society. Discussion with other divisions is a part of this process.

The executive committee recognizes that members may have concerns and questions associated with revising the name of the Division. Members should engage the committee and express their viewpoint, which could include other potential names. Contact information for the committee can be found at the end of this Newsletter.

Faster Decisions with Greater Confidence



Structure Design on the ACD/Percepta Platform

- A single environment to investigate structure modification and understand structure-property relationships
- On-the-fly property calculations
- Trainable ADME, Physicochemical, and Toxicity prediction models
- Powerful data visualization and analysis tools



ACD/Percepta

See the Software in Action

Click to **Register for Our Webinar**

Work Smarter with ACD/Percepta—A New Drug Discovery Platform for Medicinal Chemists

September 18, 2013, 11 AM EDT

Meet us at ACS Fall

Indianapolis (September 8-12, 2013) **Booth 1112**



Learn more www.acdlabs.com/leadop

Six Medicinal Chemists Named ACS Fellows

The American Chemical Society Fellows Program recognizes members of ACS for outstanding achievements in and contributions to science, the profession, and society. Six distinguished medicinal chemists are among the 2013 Fellows.

Daniel L. Flynn, is President and CEO at Deciphera Pharmaceuticals in Lawrence, Kansas.

Gunda I. Georg is a Professor and Head of Medicinal Chemistry at the University of Minnesota.

M. Katharine Holloway is a Senior Principal Scientist at Merck.

Les McQuire is Global Program Manager at Novartis.

Lisa A. Peterson is a Professor in the Division of Environmental Health Sciences, at the University of Minnesota.

Jeff Zablocki is Senior Director and Head of Cardiovascular Chemistry at Gilead Sciences.

Congratulations to these outstanding members of the Division!

Chemical Abstracts Service wants your input!

The ACS Joint Board-Council Committee on CAS (CCAS), an ACS governance committee charged with acting as an information conduit between the ACS membership and CAS management, continues to seek your input! The committee meets twice annually, in conjunction with the ACS National Meetings, and communicates via e-mail between meetings. CCAS will meet in closed session prior to the ACS National Meeting, on Friday, September 6, 2013. If you have any issues that you would like raised either at or after this meeting, please contact a member of the committee by phone or e-mail. A list of committee members appears at http://portal.acs.org/portal/PublicWebSite/about/governance/committees/cas/CNBP_030396. Someone will respond to your query as soon as possible.

Issues raised will be brought to the attention of CAS management, and responses will be disseminated to the appropriate individuals or groups as quickly as possible. Please remember that you are encouraged to contact a member of CCAS with feedback at any time, regardless of whether or not a formal call has been posted. We have also established a group on the ACS Network, <https://communities.acs.org/groups/chemical-abstracts-service-committee>, where you can post questions and read answers. CCAS now has a page on Facebook too.

Thanks very much!

Chuck Huber, for CCAS

<http://portal.acs.org/portal/PublicWebSite/about/governance/committees/cas/index.htm>

Join us for the 246th American Chemical Society National Meeting & Exposition

Chemistry in Motion
Indianapolis, IN • Sept. 8-12



Fume containment that evolves with your needs.

Protecting the operator and environment from toxic fumes, gases, vapors and particulate.

As research and laboratories evolve, AirClean® Systems continues to innovate with more sophisticated and efficient ductless fume containment solutions. From our AC600 chemical workstations to Patriot™ ductless fume hoods and ultimately the Independence™ fume hood, AirClean® Systems provides scalable, energy-efficient fume containment for a diverse range of applications.

Your innovation drives us to innovate. To find out more about AirClean® Systems' latest advancements in filtration, gas detection and energy conservation, visit <http://www.aircleansystems.com/innovate>

Visit us at ACS BOOTH #1317

AirClean® Systems
The Fume Control Experts.



Raleigh, NC USA • 919-255-3220 • 800-849-0472
www.aircleansystems.com • info@aircleansystems.com



Four Students Selected to Receive ACSMEDI Predoctoral Fellowships

The Division of Medicinal Chemistry is pleased to announce that four graduate students have been selected to receive 2013-2014 Predoctoral Fellowships. The awards, consisting of a \$26,000 stipend, are granted to predoctoral students in their third or fourth year of graduate study. Winners must be engaged in medicinal chemistry research in a Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry, or Chemistry department listed in the current ACS Directory of Graduate Research. They must also be U.S. citizens or permanent resident visa holders, and must have at least one year of graduate school remaining as of September, 2013. Two of these awards are supported by the Medicinal Chemistry Division of ACS. Two are supported through the generosity of members of the Division: Richard B. Silverman and Robert Vince have each committed to the sponsorship of Predoctoral Fellowships. The awardees for the 2013-2014 academic year are:



Timothy Senter, Vanderbilt University, Advisor: Craig Lindsley (Silverman Fellow). Tim earned his B.S. in chemistry at St. Lawrence University, where he worked under the guidance of Dr. Larry G. French on the synthesis of N-cyanoguanidine based TRPV1 receptor antagonists. In 2010, Tim joined Dr. Lindsley's lab at Vanderbilt University. His current efforts focus on novel methods for the enantioselective synthesis of heterocycles, total synthesis of biologically relevant natural products, and development of small molecules for the treatment of leukemia and CNS disorders through the modulation of protein-protein interactions.



Elizabeth Parkinson, University of Illinois, Advisor: Paul Hergenrother (Vince Fellow). Elizabeth I. Parkinson attained a B.S. in Chemistry at Rhodes College (Memphis, TN). While in Memphis, she did research in the lab of Dr. Philip Potter at St. Jude Children's Research Hospital where she focused on developing small molecule inhibitors of carboxylesterases as a strategy to ameliorate the toxicity of the anticancer agent CPT-11. She joined the lab of Prof. Hergenrother at the University of Illinois at Urbana-Champaign and is currently developing a class of small molecules specifically activated by the enzyme NQO1 as a potential targeted anticancer strategy.



Christine Kaiser, University of Arizona, Advisor: Laurence Hurley (MEDI Fellow). Christine received her B.S. in Biochemistry and Mathematics from Arizona State University, where she worked at the Translational Genomics Research Institute (TGen) focusing on new treatments for colon cancer. Currently, she is a 4th year Ph.D. student in the College of Pharmacy at the University of Arizona with Prof. Hurley. Her current work focuses on targeting the proto-oncogene KRAS at the transcriptional level by identifying compounds that interact with DNA secondary structures (G-quadruplexes and i-Motifs) formed in the KRAS proximal promoter.



Renee Bouley, Notre Dame University, Advisor: Shahriar Mobashery (MEDI Fellow). Renee studied at Grand Valley State University in Michigan, where she received a B.S. degree in Chemistry. She joined Shahriar Mobashery's group at the University of Notre Dame, researching novel antibiotics for the treatment of resistant *Staphylococcus aureus*. Renee began as an organic chemist, synthesizing various quinazolinone analogs and improving the synthetic methodology. However, she was also interested in probing the biological activity of these molecules so she began gaining experience in biochemistry, microbiology, and pharmacology.

The Division of Medicinal Chemistry would like to thank the sponsors of the Predoctoral Fellowship awards for their generosity and support (**Richard B. Silverman** and **Robert Vince**), and extend congratulations to the winners.

Drug Discovery Re-Invented Symposium

Emerging Role of Biotechs, Academics and Non-Profits
October 16-19 2013, AZ, USA

**** Registration Deadline 21st August. Register [HERE](#) ****

Speakers include: Prof. William Jorgensen (Yale University) Prof. Jef De Brabander (UT Southwestern Medical),
Dr. Bart DeCorte (Janssen Research & Development), Prof. James Barrow, (Johns Hopkins School of Medicine),
Dr. Ken Duncan ((Bill & Melinda Gates Foundation), Dr. Barry Bunin (Collaborative Drug Discovery), Dr. Leah Frye (Schrödinger),
Prof. Sean Brady (The Rockefeller University), Dr. Craig Thomas (NIH Chemical Genomics Center),
Dr. Benjamin Blass (Temple University School of Pharmacy), Prof. Kenneth Merz (University of Florida), Dr. Michael Foley (Broad Institute),
Dr. Serge L Boulet (Eli Lilly), Dr. Gabor Butora (Merck), Dr. Paul Leeson (GlaxoSmithKline), Dr. Steven Young (Retired VP Merck & Co.),
Dr. Joel Dudley (Mount Sinai School of Medicine), David Lowe (Aeglea BioTherapeutics) and many more.

FUSiON 
CONFERENCES LIMITED

Division Travel Grants

The Division of Medicinal Chemistry makes 14 grants of \$600 - \$1000 available annually to aid young chemists in presenting papers at the ACS National Meetings. Applicants must be ACS regular or student members, and not have previously received a travel award. Each University department can have only one awardee. Application deadlines are the same as the abstract deadline for each meeting. In order of priority, the following individuals will be considered for awards: Graduate Student, Postdoctoral Fellow, individual with less than five years post-Ph.D. experience. The scientific merit of the paper to be presented will also be considered. Send applications to:

John E. Macor, Ph.D.
Bristol-Myers Squibb R&D
5 Research Parkway
Wallingford, CT 06492
(203) 677-7092
john.macor@bms.com

Awardees will be notified in sufficient time so that they can pre-register for the meeting. **All travel grant recipients are required to acknowledge the Division in a slide or on their poster as a condition of accepting the award.** Awards are made at the Division business meeting, which is held at each national meeting immediately before the Sunday night poster session and mixer. Address info and a complete application appears elsewhere in this newsletter.

Invitation to Authors: *Journal of Medicinal Chemistry Perspective Series*

The Perspective series of the *Journal of Medicinal Chemistry* is designed to provide an enlightened appraisal of a field of research in which experts review the state-of-the-art for a given area or therapeutic target. Authors have editorial freedom to express their views on the strategic directions of the field of research. The Perspective series provides a forum with high visibility within the pharmaceutical industry and academia. We would like to identify a wide range of potential topics and authors to ensure that a Perspective article is published in every issue of the Journal. We would like the series to be useful to a broad range of scientists

interested in the design, discovery and development of novel medicines. We invite you to submit an idea for a Perspective, along with a brief outline of what you will cover in the manuscript. We also welcome your input regarding potential topics of interest and authors for Perspective manuscripts. Please direct correspondence or calls regarding the series to:

William J. Greenlee
MedChem Discovery Consulting
115 Herrick Avenue
Teaneck, NJ 07666-4106
Phone (908)-463-5332
william@william-greenlee.com

CALL FOR PAPERS 247th NATIONAL ACS MEETING Dallas, TX, March 15-20, 2014 ACS Abstracts System opens late August

You are invited to submit an abstract for a research presentation at the 247th National Meeting of the American Chemical Society, to be held March 15-20, 2014, in Dallas, TX. All abstracts should be submitted online using the ACS Abstract system, which will open soon. The deadline for abstract submission will also be the deadline for submission of travel grant applications, as outlined elsewhere in this Newsletter. Please watch the ACS web site or the Division Homepage, located at:

<http://www.acsmedchem.org/>

for additional information. The MEDI scientific program and abstracts will be available for download 3-4 weeks prior to the meeting, and their availability will be announced by electronic mail. For more information on programming or abstract submission, contact the Program Chair, John Macor, at

john.macor@bms.com

Division Archives Available On-line

Division newsletters, scientific programs and abstract books dating to 2002 are archived online. These documents can be downloaded in pdf format through the Division WWW page:

<http://www.acsmedchem.org>



Call for Nominations 2014 David W. Robertson Award for Excellence in Medicinal Chemistry

The Division of Medicinal Chemistry is now accepting nominations for the 2014 David W. Robertson Award for Excellence in Medicinal Chemistry. This biannual award, supported by Pfizer, Inc., is in memory of David W. Robertson, a widely respected, highly successful and creative medicinal chemist, and is intended to recognize seminal contributions by young scientists to medicinal chemistry. Nominees must be age 40 or younger at the time of nomination, can be employed in academia, industry, government or by a private research organization, and must be engaged in the research of biologically active substances. The nominee must have had a primary role in the discovery of a novel therapeutic agent(s), target(s), theoretical concept(s) in medicinal chemistry or drug discovery, and/or made a significant scientific discovery that enhances the field of medicinal chemistry.

The awardee will receive a plaque, an honorarium, and will be invited to present his/her research at an award symposium organized by the Division of Medicinal Chemistry at the Fall National Meeting of the American Chemical Society.

Nomination packages must include a current curriculum vitae, a primary letter of recommendation that clearly describes the contribution(s) and accomplishment(s) of the nominee, the role the individual played in the discovery or discoveries for which he/she is being nominated, and a second supporting letter from someone familiar with the work being recognized. The complete package should be sent electronically to the Chair of the Division:

Joel Barrish, Ph.D.
Bristol-Myers Squibb R&D
P.O. Box 4000
Princeton, NJ 08543
(609) 252-5897
joel.barrish@bms.com

Nomination packages must be received by **Friday, November 1, 2013.**



Call for Nominations 2014 Division of Medicinal Chemistry Award

Nominations are now being accepted for the 2014 Division of Medicinal Chemistry Award. This award is open to any scientist or team of scientists from the U.S. or abroad whose research has had, directly or indirectly, a significant effect on medicinal chemistry. Although other types of accomplishments (such as a new research tool) will not be excluded, emphasis will be placed on contributions to the discipline of medicinal chemistry, broadly defined, and scientists whose accomplishments have not already been previously recognized in the form of other honors. The award will be presented as a part of a special session at the 2014 National Medicinal Chemistry Symposium held in Charleston, SC, May 18-21, 2014.

Nominations must include a detailed letter describing the candidate's research accomplishments and contributions to medicinal chemistry, at least one seconding letter, and a current curriculum vitae of the nominee(s). Materials must be received by **September 6, 2013** and should be sent electronically to:

Joel Barrish, Ph.D.
Bristol-Myers Squibb R & D
P.O. Box 4000
Princeton, NJ 08543
609-252-5897
Joel.Barrish@bms.com

Nominators are encouraged to contact Dr. Barrish prior to submission.

ACS Division of Medicinal Chemistry Student Travel Grants



APPLICANTS MUST SUBMIT AN ABSTRACT SEPARATELY VIA OASYS SYSTEM

The deadline for Travel Grant applications is the same as the abstract deadline for that meeting.
All travel grant recipients are required to acknowledge the Division in a slide during oral presentations,
or on their poster as a condition of accepting the award.

* Name of Applicant for Travel Grant _____

* Degree: _____ Year Obtained _____

* Present Institution: _____

* Department: _____

*E-mail Address: _____

* Work to be reported was (check one or more):

- a. Ph.D. Thesis _____
- b. M.S. Thesis _____
- c. Postdoctoral Fellowship _____

*Supported by (indicate source of support for this work):

- a. Grant _____
- b. Department _____
- c. Other _____

Send the completed application form and a copy of the OASYS abstract to:

John E. Macor, Ph.D.
Bristol-Myers Squibb R&D, 5 Research Parkway, Wallingford, CT 06492
(203) 677-7092
john.macor@bms.com

Advertise in the ACSMEDI Newsletter

The ACSMEDI Newsletter is distributed twice a year to 9,600 medicinal and organic chemist members, and is freely accessible to all through the ACSMEDI homepage. In response to a number of inquiries, we have established the following advertising policy:

Full page:	\$900.00
One-half page:	\$500.00
One-quarter page:	\$350.00

To place an ad or obtain more information, contact the Editor at eric.walters@rosalindfranklin.edu

Encourage our Advertisers!

Please let our advertisers know that you saw their ad in *The Reaction Times*, and that you appreciate their support. Advertising revenues go directly into the Division's treasury, and they help to keep dues low.

Sponsorship for Division of Medicinal Chemistry Symposia

Division of Medicinal Chemistry symposia at National Meetings are presented in part through the financial support of sponsor companies. Sponsorship opportunities are available for all upcoming Division of Medicinal Chemistry Symposia. Symposium sponsors for national ACS meetings are acknowledged with a prominent sign outside the meeting room, and by session chairs during the symposium. In addition, a table is provided where company representatives can interact with meeting attendees, and provide promotional materials. For more information on symposium sponsorship, contact the Program Chair, John Macor (john.macor@bms.com), or the Division Chair, Joel Barrish (joel.barrish@bms.com).

Your Suggestions and Contributions Are Wanted!

The Division is revamping its website. If you have suggestions for features you would like to see there, please send them to the Secretary, Eric Walters, at eric.walters@rosalindfranklin.edu.

If you have news items that you would like to see in *The Reaction Times*, please submit them to the Newsletter Editor, Eric Walters, at eric.walters@rosalindfranklin.edu. Please put "MEDI Newsletter" in the subject line. The deadline for the Newsletter is five weeks prior to the upcoming ACS National Meeting.

ACS Division of Medicinal Chemistry
Complete Officers/LRPC List 2013

1. Regular Executive Committee Members

Chair 2013

Joel Barrish, Ph.D.
Bristol-Myers Squibb R&D
P.O. Box 4000
Princeton, NJ 08543
(609) 252-5897
joel.barrish@bms.com

Vice Chair 2013

Thomas E. Prisinzano, Ph.D.
Department of Medicinal Chemistry
University of Kansas
4035 Malott Hall
Lawrence, KS 66045-7582
(785)-864-3267
prisinza@ku.edu

Program Chair 2013-2014

John E. Macor, Ph.D.
Bristol-Myers Squibb
5 Research Parkway
Wallingford, CT 06492
(203) 677-7092
john.macor@bms.com

Secretary and Public Relations 2011-2013

D. Eric Walters, Ph.D.
Department of Pharmaceutical Sciences
Rosalind Franklin University
3333 Green Bay Road
North Chicago, IL 60064
(847)578-8613
eric.walters@rosalindfranklin.edu

Membership Chair

Yanping Xu, Ph.D.
Lilly Research Laboratories
Lilly Corporate Center
DC1910
Indianapolis, IN 46285
(317) 433-1113
xu_yanping@lilly.com

Treasurer 2012-2014

Danny L. Lattin, Ph.D.
643 Massachusetts, Suite 200
Lawrence, KS 66047
(785) 843-3460
lattind@ku.edu

Academic Councilor 2011-2013

Richard A. Gibbs, Ph.D.
Department of Medicinal Chemistry and Molecular
Pharmacology
575 Stadium Mall Drive
Purdue University
West Lafayette, IN 47907-2091
(765) 494-1456
rag@pharmacy.purdue.edu

Academic Councilor 2012-2014

David P. Rotella, Ph.D.
Department of Chemistry & Biochemistry
355 Richardson Hall
Montclair State University
Montclair NJ 07043
(973) 655-7204
rotellad@mail.montclair.edu

Industrial Councilor 2012-2014

William J. Greenlee, Ph.D.
MedChem Discovery Consulting, LLC
115 Herrick Avenue
Teaneck, NJ 07666-4106
(908) 463-5332
william@william-greenlee.com

Industrial Councilor 2013-2015

Amy Ripka, Ph.D.
SAI Life Sciences
1446 Main St.
Reading, MA 01867
amy.r@sailife.com

Past Chair 2013

Patrick M. Woster, Ph.D.
Department of Drug Discovery and
Biomedical Sciences
Medical University of South Carolina
70 President St., Room 405
Charleston, SC 29425
843-876-2453
woster@musc.edu

2. Alternate Councilors and Members-at-Large (Ad Hoc EC Members)

Academic Alternate Councilor 2011-2013

Shelli McAlpine, Ph.D.
School of Chemistry
University of New South Wales
Sydney 2052
Australia
+61-2-9385-4712
s.mcalpine@unsw.edu.au

Academic Alternate Councilor 2012-2014

Michael S. VanNieuwenhze, Ph.D.
Department of Chemistry
Indiana University
800 E. Kirkwood Avenue
Bloomington, IN 47405
mvannieu@indiana.edu

Industrial Alternate Councilor 2012-2014

Vacant

Industrial Alternate Councilor 2013-2015

John Butera, Ph.D.
Hager Biosciences, LLC
116 Research Drive, Suite 265
Bethlehem, PA 18015
(610) 849-5077
jbutera@hagerbio.com

Journal of Medicinal Chemistry Liaison 2013

Gunda Georg, Ph.D.
Department of Medicinal Chemistry
Editor, *Journal of Medicinal Chemistry*
717 Delaware Street SE
College of Pharmacy University of Minnesota
Minneapolis, MN 55414
(612)-626-6320
georg@umn.edu

Editor-in-Chief, *Annual Reports in Medicinal Chemistry* (2012-2016)

Manoj Desai, Ph.D.
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
(650) 522-5075
manoj.desai@gilead.com

Foreign Societies Liaison 2013

Thomas J. Perun, Ph.D.
Affiliated Scientific
47731 Old Houston Hwy
Hempstead, TX 77445
tjperun@aol.com

**ACS Division of Medicinal Chemistry
Long Range Planning Committee 2013**

LRPC Chair:

Thomas E. Prisinzano, Ph.D.
Department of Medicinal Chemistry
University of Kansas
4035 Malott Hall
Lawrence, KS 66045-7582
(785)-864-3267
prisinza@ku.edu

Lauren Monovich (2011-2013)
Novartis Institutes for BioMedical Research
USCA, 601-3209
100 Technology Square
Cambridge, MA 02139
(617) 871-7606
lauren.monovich@novartis.com

Nick Meanwell (2011-2013)
Bristol-Myers Squibb
5 Research Parkway
Wallingford, CT 06492
(203) 677-6679
nicholas.meanwell@bms.com

Carrie Haskell-Luevano (2011-2013)
University of Minnesota College of Pharmacy
Department of Medicinal Chemistry
8-102 Weaver Densford Hall
308 Harvard Street SE
Minneapolis, MN 55455
(612) 626-9262
chaskell@umn.edu

Craig W. Lindsley, Ph.D. (2012-2014)
Pharmacology – Center for Neuroscience Drug Discovery
12415D MRB IV (Langford)
Vanderbilt University Medical Center
Nashville, TN 37232-0697
(615)-322-8700
craig.lindsley@vanderbilt.edu

Andy J. Peat, Ph.D. (2012-2014)
GlaxoSmithKline
Five Moore Drive
Research Triangle Park, NC 27707
(919) 483-6137
andy.j.peat@gsk.com

Steven M. Firestine, Ph.D. (2012-2014)
Dept. of Pharmaceutical Sciences
3134 Applebaum Hall
Wayne State University
Detroit, MI 48202
(313)-577-0455
sfirestine@wayne.edu

Joanne Bronson, Ph.D. (2013-2015)
Director, Neuroscience Discovery Chemistry
Bristol-Myers Squibb
5 Research Parkway
Wallingford, CT 06492
Phone: 203-677-6431
Joanne.bronson@bms.com

S. David Kimball, Ph.D. (2013-2015)
Research Professor
Ernest Mario School of Pharmacy
School of Arts & Sciences
William Levine Hall, Room 328
160 Frelinghuysen Road
Piscataway, NJ 08854-8020
Phone: 848-445-6493
dkimball@pharmacy.rutgers.edu

J. Robert Merritt, Ph.D. (2013-2015)
Associate Professor
Organic and Medicinal Chemistry
Kean University: NJ Center for Science, Technology &
Mathematics
STEM Building
1000 Morris Ave., Union, NJ 07083-0411
Phone: 908-737-7226
jmerritt@kean.edu

Paul Ornstein, Ph.D. (2013-2015)
Associate Professor of Medicinal Chemistry
College of Pharmacy
Roosevelt University
1400 N. Roosevelt Blvd.
Schaumburg, IL 60173
Phone: 847-330-4504
plornstein@roosevelt.edu

Janeta Popovici-Muller, Ph.D. (2013-2015)
Associate Director, Chemistry
Agios Pharmaceuticals
38 Sidney Street
Cambridge, MA 02139
Phone: 617-649-8604
janeta.popovici-muller@agios.com

Wendy Young, Ph.D. (2013-2015)
Director, Medicinal Chemistry
Genentech Inc.
1 DNA Way
MS#18
South San Francisco, CA 94080
Phone: 650-467-7945
young.wendy@gene.com